The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prospective, randomized studies including over 750 men with various severities and etiologies of ED have found a preference for tadalafil over sildenafil by significant margins (Eardley et al 2005; Govier et al 2003; von Keitz et al 2004).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Govier et al 2003
In the citing paper
“A randomized, crossover study of 215 men with ED found 66.3% preferred tadalafil over sildenafil for initiation of ED therapy (Govier et al 2003).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Govier et al 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J., & Ignarro, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260203 · Cited by 1,006
Impact of erectile dysfunction on quality of life: patient and partner perspectives
Wagner, G., Fugl-Meyer, K., & Fugl-Meyer, A. (2000) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900594 · Cited by 118
Research works printed but not linked: 24
- McKinlay, 2000, The worldwide prevalence and epidemiology of erectile dysfunction, Int J Impot Res, 12, S6, 10.1038/sj.ijir.3900567 · DOI · Paper page
- Litwin, 1998, Health-related quality of life in men with erectile dysfunction, J Gen Intern Med, 13, 159, 10.1046/j.1525-1497.1998.00050.x · DOI · Paper page
- Rust, 1988, Marital problems and sexual dysfunction: How are they related?, Br J Psychiatry, 152, 629, 10.1192/bjp.152.5.629 · DOI
- NIH Consensus Development Panel on Impotence, 1993, 270, 83
- Aytaç, 1999, The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences, BJU Int, 84, 50, 10.1046/j.1464-410x.1999.00142.x · DOI · Paper page
- Burchardt, 2001, Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension, Int J Impot Res, 13, 276, 10.1038/sj.ijir.3900725 · DOI
- Kirby, 2001, Is erectile dysfunction a marker for cardiovascular disease?, Int J Clin Pract, 55, 614, 10.1111/j.1742-1241.2001.tb11141.x · DOI
- Buvat, 1985, Comparative investigations in 26 impotent and 26 nonimpotent diabetic patients, J Urol, 133, 34, 10.1016/S0022-5347(17)48773-8 · DOI
- O'Kane, 2001, Erectile dysfunction: Is there silent obstructive coronary artery disease?, Int J Clin Pract, 55, 219
- Hanash, 1997, Comparative results of goal oriented therapy for erectile dysfunction, J Urol, 157, 2135, 10.1016/S0022-5347(01)64695-0 · DOI
- Jarow, 1996, Outcome analysis of goal directed therapy for impotence, J Urol, 155, 1609, 10.1016/S0022-5347(01)66142-1 · DOI
- Brock, 2002, Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses, J Urol, 168, 1332, 10.1016/S0022-5347(05)64442-4 · DOI · Paper page
- Fink, 2002, Sildenafil for male erectile dysfunction: A systematic review and meta-analysis, Arch Intern Med, 162, 1349, 10.1001/archinte.162.12.1349 · DOI
- Morales, 1998, Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of, Int J Impot Res, 10, 69, 10.1038/sj.ijir.3900354 · DOI · Paper page
- Hanson-Divers, 1998, Health outcomes variables important to patients in the treatment of erectile dysfunction, J Urol, 159, 1541, 10.1097/00005392-199805000-00037 · DOI
- Jarow, 1999, Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment, J Urol, 162, 722, 10.1097/00005392-199909010-00024 · DOI
- Hatzichristou, 2000, Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year, J Urol, 164, 1197, 10.1016/S0022-5347(05)67140-6 · DOI
- McMahon, 2000, Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction, J Urol., 164, 1192, 10.1016/S0022-5347(05)67139-X · DOI
- Giuliano, 2000, Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study, J Urol., 164, 708, 10.1016/S0022-5347(05)67286-2 · DOI
- Fagelman, 2001, Efficacy, safety, and use of sildenafil in urologic practice, Urology, 57, 1141, 10.1016/S0090-4295(01)00984-0 · DOI
- Martinez-Jabaloyas, 2001, Prognostic factors for response to sildenafil in patients with erectile dysfunction, Eur Urol., 40, 641, 10.1159/000049850 · DOI
- Paige, 2001, Improvement in emotional well-being and relationships of users of sildenafil, J Urol., 166, 1774, 10.1016/S0022-5347(05)65673-X · DOI
- Marks, 1999, Treatment of erectile dysfunction with sildenafil, Urology, 53, 19, 10.1016/S0090-4295(98)00525-1 · DOI
- Wagner, 2001, Sildenafil citrate (Viagra®) improves erectile function in elderly patients with erectile dysfunction: A subgroup analysis, J Gerontol A Biol Sci Med Sci., 56, M113, 10.1093/gerona/56.2.M113 · DOI
Cited by
Yuan, J., Zhang, R., Yang, Z., Lee, J., Liu, Y., Tian, J., Qin, X., Ren, Z., Ding, H., Chen, Q., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.012 · Cited by 260
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Corona, G., Rastrelli, G., Burri, A., Jannini, E. A., & Maggi, M. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1130126 · Cited by 71
Metadata
- Authors
- Govier, F., Potempa, A.-J., Kaufman, J., Denne, J., Kovalenko, P., & Ahuja, S.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 25
- Issue
- 11
- Pages
- 2709-2723
- ISSN
- 0149-2918
- Cited by
- 77
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
